We infused recombinant human tumor necrosis factor alpha (rhTNFJ, lymphotoxin (rhLT), and Escherichia coli 0111:B4 lipopolysaccharide (LPS) into anesthetized sheep with a lung lymph fistula to compare their effects on systemic and pulmonary bemodynamics, lung lymph dynamics, and eicosanoid release. rhTNF,, (25-150 pg/kg, n-6 sheep), but not rhLT (25 /ig/kg, n=3), rapidly increased lung lymph and plasma levels of 6-kcto-prostaglandin F la (6-k-PGF,,,) and caused profound systemic vasodilation and hypotension. Meclofenamate pretreatment (10 mg/kg) of three other sheep given 25 Mg/kg rhTNF., prevented the increase of lymph and plasma 6-k-PGF la levels, systemic vasodilation, and the early (<2 hrs) but not the late (4-6 hours) hypotension caused by rhTNF,,. LPS (1 /ug/kg, n = l l ) induced a briefer increase of lymph 6-k-PGF ln levels than did rhTNF a while plasma 6-k-PGF,,, levels did not increase. LPS induced more gradual hypotension than did rhTNF a but did not cause systemic vasodilation. LPS and rhTNF^ but not rhLT, increased lymph thromboxane Bj (TXBj) levels during the first hour of study, whereas only LPS acutely increased plasma TXB 2 levels. LPS caused acute pulmonary vasoconstriction and greater acute pulmonary artery hypertension than did either rhTNF,, or rhLT. Whereas LPS-treated sheep required less fluid transfusion than rhTNF a -treated sheep to maintain mean systemic arterial pressure greater than 50 mm Hg, LPS infusion caused a greater increase of lung lymph protein clearance. rhTNF,, caused minimal alterations of lung microvascular permeability. We conclude that eicosanoid mediators contribute importantly to differences of systemic and pulmonary hemodynamics caused by these agents in sheep. 
In contrast, LT, which is produced by activated lymphocytes, was not detectable in serum by bioassay after LPS infusion into human volunteers. 14 Although LT and TNF a share approximately 30% homology of amino acid sequence, appear to bind to a common receptor, 2 and have many similar effects on endothelial cells, 45 the role of LT in mammalian defense against infection is unknown. Furthermore, whereas LPS-induced lung injury has been studied extensively in animals, 17 the roles of both TNF a and LT in the early evolution of LPS-induced lung injury are unknown.
Our study compared the effects of intravenous infusions of rhTNF,,, rhLT, and Escherichia coli LPS on anesthetized sheep to discover qualitative differences of response to these agents. In addition to measuring pulmonary and systemic hemodynamics, we sought evidence of lung injury by measuring lung lymph flow, transvascular protein clearance, and lung extravascular water content. Levels of the eicosanoids thromboxane B2 (TXB2), the hydrolysis product of the pulmonary vasoconstrictor and bronchoconstrictor TXA 2 , and 6-keto-prostaglandin F l a (6-k-PGF la ), a metabolite of the vasodilator prostacyclin, were measured by radioimmunoassay in plasma and lung lymph. Because we measured a marked increase of eicosanoid release after infusion of rhTNF OT we also studied the effects of a cyclooxygenase inhibitor in sheep given rhTNF a . To avoid hypovolemic shock caused by LPS or the cytokines, we attempted to maintain the mean systemic arterial pressure above 50 mm Hg and the pulmonary artery occlusion pressure (PAOP) at the baseline value ±2 mm Hg by transfusion of lactated Ringer's solution (LR).
Materials and Methods

Animal Preparation
Thirty-two Hampshire sheep (15-39 kg) were prepared for study. Each animal was anesthetized with 0.5-0.75% halothane (Halocarbon Laboratories, Hackensack, New Jersey), intubated, and ventilated by a constant-volume respirator (model 613, Harvard Apparatus, Millis, Massachusetts) with pure oxygen at a tidal volume of 11-12 ml/kg and a rate of approximately 12-14 breaths/min to establish the baseline (prestudy) arterial PCO2 at 35-45 mm Hg. Positive end-expiratory pressure of 5 cm water was applied. Pancuronium chloride (Organon, West Orange, New Jersey), 0.5-1.0 mg, was infused every 2-4 hours to provide muscle relaxation.
Sterile femoral incisions were made, and polyvinyl catheters (North American Instrument, Hudson Falls, New York) were advanced to midthoracic level through both femoral arteries and one femoral vein to measure mean systemic arterial blood pressure (SAP) and heart rate (HR) and to sample blood. A 7.5F flow-directed thermodilution pulmonary artery (PA) catheter (model 73R6067, Electracatheter, Rahway, New Jersey) was passed via an 8F introducer sheath with side-port (Cordis, Miami, Florida) through the right jugular vein to monitor mean pulmonary artery pressure (PAP) and PAOP.
An acute pulmonary lymph fistula was established in all sheep following the method of Staub et al. 18 The efferent lymph duct of the caudal mediastinal node was cannulated with a silicone catheter (medical grade tubing, 0.64 mm i.d. x 1.19 mm o.d., Dow Corning, Midland, Michigan). The tail of the mediastinal lymph node was ligated at the free margin of the inferior pulmonary ligament to decrease the contribution of nonpulmonary lymph. The catheter was exteriorized, and the chest wall was closed.
To resolve pulmonary atelectasis, which often developed during surgery and study, the lungs were briefly inflated every 30-60 minutes with peak airway pressures of 50 cm water. An external heater and drapes maintained the pulmonary artery temperature at 38.5-40.0° C.
Hemodynamic and Airway Measurements
SAP, central venous pressure (CVP), PAP, PAOP, and HR were monitored continuously using calibrated pressure transducers (model 1280C, HewlettPackard, Palo Alto, California) zeroed at left atrial level and an eight-channel recorder (model 7758B, Hewlett-Packard). Mean cardiac output was determined by thermodilution as the mean of three measurements using 5-ml injections of 0° C LR solution and a cardiac output computer (model COC 4000, Electra-cather). Cardiac index was derived by dividing cardiac output (milliliters per minute) by the animal's body weight (kilograms). Systemic and pulmonary vascular resistance indexes (SVRI and PVRI, respectively) were calculated and 504
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adjusted for body weight using standard formulae: SVRI = (SAP-CVP)/cardiac index and PVRI= (PAP-PAOP)/cardiac index. Cardiac index, SVR1, and PVRI were measured every 30 minutes throughout the study, except during the initial 1-hour period (t=0-60 minutes) when they were measured every 15 minutes.
Airway pressure was monitored continuously using a pressure transducer (model 267BC, HewlettPackard) connected to a side port at the proximal end of the endotracheal tube. Airway pressure was zeroed to atmospheric pressure.
Hematologic Studies
At selected times, simultaneous arterial and mixed venous blood samples (4 ml each) were aspirated into plastic syringes and immediately injected into iced, glass tubes containing 50 /AI of 15% EDTA (Terumo Medical, Elkton, Maryland) and 100 fig indomethacin. Following measurement of hematocrit (Adams Autocrit Centrifuge, Clay Adams, Parsippany, New Jersey), arterial and venous leukocyte counts (Coulter cell counter, model Z, Coulter Electronics, Hialeah, Florida), the samples were centrifuged at 2,00Qg for 10 minutes at 4° C. The plasma was aspirated, and the total protein concentration was measured with a refractometer (model 10400A, American Optical, Buffalo, New York). The samples were stored in polypropylene tubes at -70° C for later analysis of eicosanoid levels.
Arterial and mixed venous blood pH, PcOj, and PO2 were determined on 2 ml anerobically drawn, heparinized blood samples that were stored in ice until they were assayed (pH/Blood Gas Analyzer, model 170, Corning Medical, Medfield, Massachusetts). The right-to-left pulmonary shunt fraction (QS/QT) was calculated by a standard formula. 19 
Lymph Studies
Following the termination of surgery, lung lymph was collected every 15 minutes into iced, glass tubes containing EDTA (Terumo Medical) and 100 fig indomethacin. Lung lymph flow (Ql) was recorded, and the lymph protein concentration was measured with the refractometer. The samples were then processed and stored in the same fashion as the EDTA-containing blood samples for assay of eicosanoid levels.
The ratio of lymph total protein concentration to plasma total protein concentration (L/P) was calculated, and the lung transvascular plasma protein clearance (Clp) was estimated by the following formula: Clp=L/PxQl.
Biochemical Assays
Arterial plasma and lymph levels of TXB2 and 6-k-PGFi a were determined by radioimmunoassay as described previously 20 -21 using antisera provided by Dr. L. Levine. 22 Following termination of surgery, all animals were observed for a minimum of 2 hours (t=-120 to t=0 minutes) to establish stable physiological baseline measurements. During this period, LR was infused at 15 ml/kg/hr to replace fluid and electrolyte losses due to orogastric suction and extravascular fluid shifts due to surgery and anesthesia.
Six groups of sheep were studied (Table 1) . Group 1 sheep (n=6) were infused with increasing doses of rhTNF a (Genentech, South San Francisco, California). rhTNF a was supplied in aqueous solution at a concentration of 0.5 mg/ml with specific activity on murine fibroblasts of 5.2xlO
7 IU/mg. The endotoxin content was measured at less than 0.018 ng/mg rhTNF o by limulus amoebocyte lysate assay. rhTNF tt was stored at -20° C until 30 minutes before infusion. From t=0 to t=5 minutes, we infused one of the following doses of rhTNF a : 25, 75, 100, or 150 /ig/kg. With the supportive therapy described below, no significant differences of systemic and pulmonary hemodynamics were measured during the first 4 hours after challenge in sheep given either 25 /xg/kg or those given 75-150 Mg/kg; thus, these results were pooled and are presented as rhTNF a 25-150 /ig/kg rhTNF a (group 1). A dose of 10 Atg/kg rhTNF a was given to two additional sheep not included in group 1; results from these sheep are discussed separately. This range of doses (10-150 /ig/kg) was chosen because the estimated peak rhTNF a concentrations in sheep blood (8-120 nM/1) overlapped the levels (1-50 nM/1) measured in rabbits given LPS u and dogs given rhTNF a . In three sheep given 75, 25, and 10 /ig/kg rhTNF a , respectively, the rhTNF a concentrations in selected lymph and arterial plasma samples were assayed by ELISA (enzyme-linked immunosorbent assay), (courtesy of Dr. Anthony Cerami, Laboratory of Medical Biochemistry, Rockefeller University, New York, New York and Dr. Stephen F. Lowry, Laboratory of Surgical Metabolism, Cornell University, Ithaca, New York). The lower limit of detection of this assay was 34 pg/ml (approximately 0.OO2 nM/1).
Because rhTNF a infusion caused prostacyclin release, group 2 sheep (n=3) were pretreated with a meclofenamate infusion (Warner Lambert, Ann Arbor, Michigan), 10 mg/kg dissolved in 3 ml ethanol and 150 ml LR solution, from t=-5 to t=0 minutes, and then given 25 pig/kg rhTNF a over the next 5 minutes. A dose of 25 Mg/kg, rather than 10 Mg/kg, rhTNF a was infused because it was the lowest dose that caused a 25% or greater decrease of SAP during the first 3 hours of study. The endotoxin content of meclofenamate was measured by limulus amebocyte hysate assay to be approximately 0.2 ng/mg meclofenamate (limulus amebocyte lysate assay performed by Associates of Cape Cod, West Falmouth, Massachusetts).
To contrast the effects of equal weights of rhTNF o with rhLT, group 3 sheep («=4) received rhLT (specific activity of 1.2X10 8 U/mg, Genentech), 25 Mg/kg dissolved in 10 ml LR solution and infused from t=0 to t=5 minutes. The endotoxin content of rhLT was 0.062 ng/mg rhLT. Group 4 sheep (/i=2) received meclofenamate alone (10 mg/kg). Group 5 sheep (n=4) served as controls; they underwent all the surgical procedures but received no drug treatment. All infusions were given through the femoral vein catheter. The maximum amount of contaminant endotoxin injected with the drug preparations into each sheep was 0.003 ng/kg in group 1, 0.002 ng/kg in group 3, and 2 ng/kg in groups 2 and 4. Infusion of 2 ng/kg Serratia marcescens LPS does not cause detectable pulmonary vascular responses or leukopenia in sheep. 23 To contrast the physiological effects of rhTNF a and rhLT with those of E. coli LPS, 11 sheep (group 6) were prepared in a similar fashion to the sheep given the cytokines. E. coli 0111B:4 LPS (1 Mg/kg, single lot, Westphal method, Difco, Detroit, Michigan) was then infused from t=0 to t=5 minutes. Seven sheep were studied before the TNF study was started; four sheep were studied during the TNF study to confirm the consistency of our technique and results. The measurements in these LPS groups were statistically similar; thus, the LPS data are grouped together.
After the onset of study, LR was initially infused at 4-5 ml/kg/hr. Fluid transfusion was subsequently increased, if necessary, to maintain mean SAP greater than 50 mm Hg and PAOP at baseline (t=0 minutes) levels ±2 mm Hg. The volume of infused fluid was recorded hourly. Vasopressor therapy was not given. All groups of sheep survived at least 4 hours, and the majority were studied for 6 hours after initiation of the study (t=0 to t=240-360 minutes). The: studies using 150Land 75 Mg/kg rhTNF a were terminated after 4 hours due to our inability to maintain SAP greater than 50 mm Hg despite rapid volume transfusion. A third study, infusion of 25 Mg/kg rhTNF,,, was terminated after 4 hours due to technical problems with monitoring.
Before the animals were killed, 4 ml blood was withdrawn into EDTA-containing tubes and frozen. Each animal was killed with intravenous phenobarbital and potassium chloride. The lungs were excised, passively drained of blood for several minutes, double wrapped in plastic bags, and stored at -20° C. Lung extravascular water content was determined after thawing the lungs. The right and left lungs were separated and dissected to remove bronchi greater than 5 mm diameter. The percentage of lung extravascular water content was determined using the method of Peterson et al. 24 
Statistical Analysis
All data are expressed as mean±SEM. Changes of each parameter over time within and between the study groups were evaluated with multivariate analysis of variance for repeated measures as implemented in the SAS statistical programs (version 5.16, SAS Institute, Cary, North Carolina). Planned comparisons between mean values at baseline (before drug treatment) and at subsequent times within each treatment group were performed using the F test and the two-tailed t test while contrasting the responses of the control group and the selected study group. Baseline values in the control and treatment groups were compared using a one-way analysis of variance and t tests. Planned comparisons were tested individually at a 0.05 significance level. Post hoc comparisons within a selected variable were tested at a simultaneous 0.05 level according to Bonferroni's inequality. 25 The Pearson product-moment correlation coefficient was used to measure the association between changes of selected biochemical and hemodynamic variables.
Results
Systemic Hemodynamics and Fluid Transfusion Requirements
Within 15-30 minutes of rhTNF o infusion, both SAP ( Figure 1 , top) and SVRI decreased profoundly when compared with the other treatment groups. SVRI decreased from 805±95 to 534±63 mm Hgxmin/ 1 by 30 minutes (/><0.01 differs from baseline) and remained near this level for the duration of study (594±138 mm Hgxmin/l at 6 hours). Vigorous fluid transfusion, up to five times the average rate given to untreated control sheep, was required to maintain SAP above 50 mm Hg and PAOP at baseline values ±2 mm Hg (Table 2 ). Sheep given 10 Mg/kg rhTNF a experienced less decrease of SAP and SVRI (data not shown,/?<0.05) and did not require an increased rate of fluid infusion (Table 2) .
Meclofenamate pretreatment completely prevented the decrease of SVRI caused by a subsequent infusion of 25 ^g/kg of rhTNF Q (SVRI was 823 ±35 mm Hgxmin/l at 0 minutes and was never less than 759±68 mm Hgxmin/l). Meclofenamate pretreatment also attenuated (/><0.05) the early (<2 hours) decrease of SAP caused by 25 Mg/kg rhTNF a but not the later systemic hypotension (SAP was 53 ±4 mm Hg at 6 hours, p=0.005 differs from baseline). Average fluid transfusion rates for meclofenamate+rhTNF a sheep were approximately 50% less than the average fluid transfusion rate required by sheep given 25 Mg/kg rhTNF a without a cyclooxygenase inhibitor ( 
TIME (MINUTES)
In contrast to sheep given rhTNF,,, sheep given 1 jig/kg E. coli LPS had a more gradual decrease of SAP and markedly reduced fluid transfusion requirements. Furthermore, SVRI did not decrease at any time (data not shown). In sheep given 25 /ig/kg rhLT, both SAP and SVRI decreased 3-4 hours after infusion. Whereas SAP recovered toward baseline level by 6 hours, the decrease of SVRI persisted (SVRI fell from a baseline value of 902±99 to 672±55 mm Hgxmin/1 at 4 hours and 489±58 mm Hgxmin/1 at 6 hours, /?<0.01 differs from baseline). SVRI of sheep given rhLT was comparable to the concomitant SVRI at 6 hours in sheep given 25-150 Mg/kg rhTNF a (594+138 mm Hgxmin/1). The fluid transfusion rates in sheep given rhLT were less than half the rates required after 25 /tg/kg rhTNF a (Table 2) .
HR and CVP did not change significantly in any study group (data not shown). Fluid transfusion maintained a stable PAOP at baseline ±2 mm Hg in all treatment groups (data not shown).
Pulmonary Hemodynamics and Cardiac Index
LPS infusion caused a biphasic increase of PAP (Figure 1, middle) , which nearly doubled to 30 mm Hg at 30 minutes, returned toward baseline value after 2 hours, then gradually increased again to approximately 26 mm Hg after 6 hours. Changes of PVRI paralleled the changes of PAP: PVRI quadrupled at 30 minutes (increasing from 64±7 to 253±52 mm Hgxmin/l,/?<0.001), rapidly decreased to nearbaseline levels during the next 1-2 hours, then increased to approximately three times baseline value after 6 hours (p<0.001, value differs from baseline data not shown).
In contrast to LPS-treated sheep, rhTNF a infusion caused only a minor increase of PAP during the first hour (Figure 1 , middle,/><0.05 increase of PAP in rhTNF a -treated sheep differs from concomitant LPS-induced increase of PAP). PAP in rhTNF a sheep remained elevated at 6 hours. We also measured a gradual increase of PVRI which became statistically significant only after 6 hours (increasing from 86±13 to 239±44 mm Hgxmin/1, p<0.001), and which was comparable to the LPS-induced PVRI at 6 hours.
Meclofenamate pretreatment augmented both PVRI (/?<0.05) and PAP (p<0.05) at 60 minutes to values greater than the concomitant PVRI and PAP in sheep given rhTNF a alone. Meclofenamate+rhTNF a treatment increased PVRI from 66±13 to 160±29 mm Hgxmin/1 after 1 hour (p<0.01 differs from baseline), whereas PVRI did not change at 60 minutes in sheep given rhTNF a alone. PAP increased in meclofenamate+rhTNF tt sheep from 15 ±0 to 24 ±1 mm Hg at 60 minutes (p <0.001 differs from baseline). In contrast, PAP increased minimally in sheep given rhTNF a alone (Figure 1, middle) . However, after 6 hours, PAP and PVRI in meclofenamate+ rhTNF a sheep were comparable to values measured in sheep given rhTNF a alone.
rhLT infusion induced a minor increase of PAP only during the first hour which was comparable to the rhTNF a -induced increase of PAP ( Figure 2) ; however, PVRI did not change at any time.
Cardiac index (Figure 1 , bottom) in LPS-treated sheep decreased briefly by approximately 30% during the acute LPS-induced pulmonary vasoconstriction (at 30-45 minutes), recovered after 1 hour, then decreased more gradually over 4-6 hours. Cardiac index decreased gradually in rhTNF atreated sheep to approximately 50-60% of baseline value at 6 hours. Cardiac index in meclofenamate+rhTNF a -treated sheep decreased by 40-50% (/><0.05) at 2 hours and remained at this level for the remainder of the study. Notably, the decrease of cardiac index in rhTNF a -treated sheep occurred 4-5 hours after the decrease of SAP, whereas cardiac index decreased concomitantly with the decrease of SAP in sheep given either LPS or meclofenamate+rhTNF a . Cardiac index did not decrease in either control or rhLT-treated sheep.
Infusing meclofenamate alone caused a small but significant increase of PVRI, but not of PAP, which was accompanied by a slow decrease of cardiac index (from 134±8 at 0 minutes to 92±11 mlxkg/ min at 6 hours,/?<0.05).
Airway Pressure
Peak airway pressure increased 30 minutes after LPS infusion and remained elevated for most of the study (Table 3) , whereas it increased only after 3 hours in sheep given rhTNF o . In addition, several of the LPS-treated sheep, but none of the rhTNF atreated sheep, developed wheezing by the end of study. Airway pressure did not change in any of the other study groups.
Lung Lymph Dynamics (Figure 2)
Ql and Clp rates increased within 30 minutes after infusion of LPS and continued to rise to approximately three to four times baseline flow rates after 6 hours. The L/P ratio after LPS decreased by 13% after 2 hours (p<0.05, data not shown), then returned to baseline values during the next hour.
In sheep given rhTNF^ Ql and Clp increased more slowly and to lower peak flow rates than those measured after LPS infusion (p<0.05). In contrast to the LPS-treated sheep, the L/P ratio in the rhTNF a sheep slowly increased by 16% after 3-4 hours (p<0.05), then returned to baseline value during the following 2 hours (data not shown). Notably, infusion of 10 /vtg/kg rhTNF a produced a marked increase of the L/P ratio (from 0.70±0.01 at t=0 minutes to a peak value of 0.88±0.01,/?<0.05). This dose of rhTNF a increased Ql in both sheep (from 2.5±0.6 to a peak flow of 5.6±1.3 ml/15 min).
Meclofenamate pretreatment attenuated (p<0.05) the small increases of Ql and Qp during the first 4 hours after rhTNF a infusion but did not modify either the subsequent increases of Ql and Clp (meclofenamate+ rhTNF a data not shown) or the increase of the L/P ratio.
rhLT infusion caused a 15% increase of the L/P ratio after 3 hours, which, in contrast to the L/P ratio in rhTNF a -treated sheep, remained elevated at 6 hours. Ql and Clp after rhLT increased later than in sheep given rhTNF a but were comparable to the values in rhTNF a -treated sheep at 6 hours.
Biochemical Studies
6-k-PGF la measurements. Concomitant with the decreases of SAP and SVRI, both lung lymph and arterial plasma levels of 6-keto-PGFi a increased markedly within 15-30 minutes after rhTNF a infusion and remained elevated throughout the study with lymph levels (Figure 3 ) consistently two to five times higher than the simultaneous plasma levels (plasma data not shown). Infusion of 150 Mg/kg rhTNF a into one sheep caused peak lymph and arterial plasma 6-k-PGFi a levels of nearly 30 ng/ml and 6 ng/ml, respectively. Infusion of 10 |ig/kg rhTNF a (n=2 sheep) produced smaller peak 6-k-PGF la levels (from 0.53±0.04 to 1.71+0.23 ng/ml in lymph and from 0.25±0.03 to 0.58±0.07 ng/ml in plasma, p<0.05 both values differ from baseline).
The peak lymph levels of 6-k-PGF la correlated with the infused dose of rhTNF a (r=0.92, p<0.001), whereas the increase of lymph 6-k-PGF la levels, but not arterial 6-k-PGF la levels, correlated with the reduction of SAP (r=-0.77, p<0.001) during the first hour after fhTNF a infusion (10-150 )
Compared with sheep given rhTNF,,, lung lymph 6-k-PGF la levels in LPS-treated sheep increased more slowly and returned more quickly to baseline values ( Figure 3) ; arterial plasma 6-k-PGF 1(I levels did not increase after LPS infusion. The peak lymph levels of 6-k-PGF la (1-6.2 ng/ml) after LPS infusion overlapped the peak lymph 6-k-PGFi a levels (1.5-5.9 ng/ml) after infusion of 10-100 fig/kg rhTNF o (lymph 6-k-PGF la levels after 150 ^g/kg rhTNF a are noted above). The decrease of SAP in LPStreated sheep did not correlate with either lymph or arterial 6-k-PGF la levels.
Lymph and plasma levels of 6-k-PGF la did not change in the other study groups.
Thromboxane B 2 measurements. LPS infusion caused a marked elevation of TXB2 levels in both lung lymph ( Figure 4 ) and arterial plasma (data not shown), which peaked at 1 hour, concomitant with the acute increase of PAP (Figure 1, middle) and PVRI. Lymph TXBj levels increased from 1.5 to 9 ng/ml during the first hour, decreased to baseline values during the next several hours, and were consistently 1.5-3.5 times the simultaneous plasma TXR, levels.
In contrast to LPS-treated sheep, rhTNF a infusion caused a small increase of lymph TXB2 levels at 15 and 30 minutes (Figure 4 ) whereas we measured a minor increase of plasma TXB? levels (<1 ng/ml) in rhTNF a -treated sheep at 3-4 hours. The peak lymph and plasma levels of TXB? did not correlate with the dose of rhTNF a infused. Plasma and lymph TXBj levels did not increase in the other study groups.
rhTNF a measurements. Assay of arterial plasma and lung lymph rhTNF a concentrations in three sheep given 10, 25, and 75 ^g/kg > respectively, demonstrated that (Table 4) 1) lymph concentrations of approximately 1.9-4.9 nM/1 appeared within 15 minutes after rhTNF a infusion and peaked after 30-60 minutes at approximately 4.2-14.2 nM/1, 2) peak lung lymph concentrations in each of these sheep were less than one half the peak plasma concentrations, 3) rhTNF levels remained measurable in both lymph and plasma after 4 hours of study.
Additional Hematologic Studies
In all sheep, infusion of LPS and all doses of the cytokines caused severe leukopenia within 30 minutes, which persisted throughout the study ( Figure  5 ). The leukopenia developed more quickly after infusion of the cytokines than after LPS. Meclofenamate pretreatment did not modify the leukopenia. No transpulmonary arteriovenous leukocyte gradients were measured in any group. Hematocrit remained stable in all groups despite blood sampling and differences of fluid infusion rates. Plasma protein concentration gradually decreased 35-40% by the end of study in sheep given either rhTNF a or rhLT, by approximately 25% after meclofenamate+-rhTNF,, infusion, and by 20% after LPS infusion Treatments: recombinant human tumor necrosis factor alpha (rhTNFJ 25-150 /ig/kg; M+rhTNF^, meclofenamate (10 mg/kg)+rhTNF o 25 /ig/kg; recombinant human lymphotoxin (rhLT) 25 jig/kg; LPS, Escherichia coli lipopolysaccharide 1 pg/kg; Peak airway pressure did not change in sheep given meclofenamate alone (10 mg/kg).
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•p<0.05 significant change of variable compared with time-matched change in control group. Tp<0.05 significant difference of values at t=0 minutes between treatment and control groups.
( Table 5 ). Plasma protein slowly decreased by 18% in sheep given 10 /xg/kg rhTNFB lood Gas Studies Arterial Po 2 decreased profoundly and Qs/Or increased markedly by the end of study in four of the six sheep given rhTNF a (Table 6 ). Arterial pH decreased by the end of study in all rhTNF a -treated sheep and less in sheep given meclofenamate (p<0.05, rhTNF,, vs. meclofenamate+rhTNFJ. Changes of QS/QT, arterial PQ2 and pH were not measured in the other study groups. Arterial PcOj was stable in all except two sheep given rhTNF a (data not shown).
Pathology Studies
Gross examination of the lungs at the end of study revealed that, despite frequent lung inflations to minimize atelectasis, sheep treated with 75-150 (6- /xg/kg rhTNF a had widespread atelectasis of dependent lung regions. In contrast, one of the three sheep given 25 ^g/kg rhTNF a had moderate atelectasis of the dependent lung, while the other two sheep had minor atelectasis. None of the other lungs demonstrated visible atelectasis.
Calculations of lung extravascular water content did not differ between the control group and any other study group (all ranged from 77.1% to 81.1% water by weight). These results are similar to the lung extravascular water content values measured previously in our laboratory in control sheep (78.1±0.6%) 26 and in awake sheep 2 hours after infusion of E. coli 0111:B4 LPS, 1
Discussion
Our study compared the effects of intravenous infusions of rhTNF M rhLT, and E. coli LPS into sheep to measure qualitative differences of physio- logical and eicosanoid responses to these agents. Our study provides evidence that eicosanoid mediators contribute importantly to physiological responses caused by infusion of rhTNF,, but not after the same dose of rb.LT. We also learned that the pulmonary and systemic hemodynamic and eicosanoid responses to LPS infusion differ from those produced by rhTNF,,.
Infusion of 25-150 ju.g/kg rhTNF Q caused rapid and marked increases of both lung lymph and plasma levels of the stable and inactive prostacyclin metabolite, 6-k-PGFi a . These increases were associated with rapid decreases of SAP and SVRI. Cyclooxygenase blockade with meclofenamate prevented the increases of 6-k-PGF, a levels, the decrease of SVRI, and attenuated the early (<2 hours), but not the late (4-6 hours), decrease of SAP caused by infusing 25 /tg/kg rhTNF a . Meclofenamate reduced the fluid transfusion rate required to maintain SAP above 50 mm Hg and PAOP near prestudy levels. These results suggest that the early decrease of SAP after rhTNF o infusion is due primarily to increased concentrations of eicosanoid vasodilators whereas the late decrease of SAP may partly be due to increased systemic vascular permeability and loss of intravascular fluid and solutes.
In contrast to these results, lymph and plasma 6-k-PGF la levels in sheep given 1 yxg/kg of E. coli LPS increased slightly later than in the rhTNF a sheep and returned more quickly to baseline values. SAP also decreased later in sheep treated with LPS than in sheep given rhTNF^ Whereas the initial decrease of SAP correlated with the increase of lymph 6-k-PGF la levels in rhTNF a -treated sheep, these variables did not correlate in sheep given LPS. Notably, SVRI did not decrease after LPS infusion; SVRI did not decrease in other studies of awake sheep infused with 1 /xg/kg of E. coli LPS. 29 Thus, LPS and rhTNF a cause differing patterns of prostacyclin release, systemic vasodilation, and systemic hypotension. The dose of LPS that we examined caused briefer prostacyclin release and less systemic vasodilation than did 25-150 /ig/kg rhTNF^ yet, this dose of LPS caused greater release of thromboxane into lung lymph and plasma, pulmonary vasoconstriction, and greater pulmonary artery hypertension during the first hour of study. Acute pulmonary hypertension in sheep has been reported after infusing a wide range of doses (0.07-1.33 Mg/kg) of E. coli 0127:B8 LPS 29 ; the LPS-induced pulmonary hypertension can be blocked by pretreatment with cyclooxygenase inhibitors. 17 ' 28 -30 Although meclofenamate pretreatment blocked prostacyclin release and reduced fluid transfusion requirements, it did not modify the increase of the L/P ratio, lung lymph flow, or protein clearance 4-6 hours after rhTNF,, infusion. The increase of lung lymph flow in sheep given 25-150 Mg/kg rhTNF a may be partly due to major fluid transfusion, which was associated with a decreased plasma protein concentration. However, fluid transfusion was not the sole determinant of the increased lymph flow: the two sheep given 10 jtg/kg rhTNF a did not require significant fluid transfusion (Table 2) and had stable plasma protein concentrations, but both of these sheep demonstrated an increased L/P ratio and lung lymph flow. Thus, rhTNF tt may have caused a minor increase of pulmonary microvascular permeability.
The effects of LPS and rhTNF a on lung lymph measurements contrast in several ways. First, LPS caused greater early increases of Ql, Clp, and PAP than did rhTMv Cyclooxygenase blockade of sheep given LPS attenuates the early, acute pulmonary hypertension and the carry, but not late, increases 30 Second, whereas 1 ^g/kg LPS induced briefer release of prostacyclin, no systemic vasodilation, and lower fluid transfusion requirements than did 25-150 Aig/kg rhTNF OT LPS caused a greater increase of lung lymph transvascular protein clearance after 6 hours. Our results suggest that differences of eicosanoid mediator profile and pulmonary hydrostatic pressure are important determinants of the early differences of Ql and Clp between sheep given LPS and rhTNF a . Subsequent differences of Ql and Clp appear due to the greater increase of pulmonary microvascular permeability caused by LPS infusion. As a putative mediator of the lethal effects of LPS in animals, it is possible that rhTNF a partly contributes to the increase of lung microvascular permeability after fig/kg rhTNF,, caused less thromboxane release and acute pulmonary vasoconstriction, a smaller increase of pulmonary artery pressure, and more gradual increase of airway pressure than did LPS challenge. However, sheep given 75-150 /ig/kg rhTNF a had marked atelectasis, severe right-toleft lung shunt, and marked hypoxemia at 6 hours, although these changes did not develop consistently in sheep given lower doses of rhTNF a . Atelectasis, increased shunt, and hypoxemia did not occur in LPS-treated sheep, which contrasts with the LPS-induced hypoxemia in other sheep studies. 17 Calculation of extravascular lung water content in our study demonstrates that, at the doses we studied, neither LPS nor rhTNF a caused major pulmonary edema. Notably, meclofenamate pretreatment attenuated both the fluid transfusion requirements and the increase of airway pressure in sheep given 25 yxg/kg rhTNF,,. Because sheep treated with 25 /tg/kg rhTNF a did not consistently develop an increased shunt fraction or hypoxemia, we could not assess the effect of meclofenamate on these variables. Our results suggest that cyclooxygenase, and perhaps lipooxygenase products, as well as major fluid transfusion may contribute to airway closure and atelectasis, increased shunt fraction, hypoxemia, and increased airway pressure caused by infusion of rhTNF a . We do not know why meclofenamate acutely augmented the rhTNF ainduced increase of PAP and PVRI. In contrast, cyclooxygenase inhibitors attenuate both the acute LPS-induced decrease of dynamic airway compliance and the early increase of pulmonary artery pressure in sheep. 17 Infusion of rhTNF^, but not LPS, caused metabolic acidemia. Meclofenamate treatment attenuated this acidemia, which appears similar to indomethacin blocking rhTNF a -induced acidemia in rats. 9 The precise cause of the acidemia is unknown. The ability of meclofenamate to ameliorate the acute rhTNF a -induced systemic hypotension and reduce fluid transfusion requirements in sheep suggests that eicosanoids contribute to systemic hypoperfusion and acidemia. Studies in which cyclooxygenase inhibitors were administered to animals prior to infusion of either rhTNF a 9 or LPS Infusion of 25 /ig/kg rhLT did not cause increased plasma or lymph TXBj or 6-k-PGF la levels, acute pulmonary hypertension, or pulmonary atelectasis. Infusing rhLT caused more gradual systemic vasodilation and hypotension than did 25 required markedly lower fluid transfusion rates, and did not cause acidemia. However, rhLT infusion increased the L/P ratio and caused small increases of Ql and Clp after 6 hours which were statistically comparable to those induced by rhTNF,, (Figure 2) . These results suggest that 6 hours after infusion, both rhLT and rhTNF o may cause a minor increase of lung microvascular permeability. The change is small and occurred concomitantly with a progressive reduction of plasma protein levels, making precise interpretation difficult. Because we measured plasma levels of rhTNF^ but not rhLT, we cannot state with certainty that at an equivalent concentration, rhLT is a weaker stimulus for many of these changes, including prostacyclin release into plasma and lymph. However, sufficient quantities of rhLT were administered to cause marked leukopenia and systemic vasodilation at 6 hours.
The doses of rhTNF a infused into our sheep were weight-adjusted and derived from comparison with the peak serum TNF a levels measured following infusion of 6-10 /ig/kg E. coli 0127:B8 LPS into rabbits. 13 In rabbits, detectable serum TNF a levels appear within 15 minutes after LPS infusion, peak after approximately 2 hours at 1-50 nM/1, and return to baseline levels after 5 hours. Thus, the rhTNF a levels in our study (Table 4) overlap those reported in rabbits after LPS infusion. Because the species-specific differences of TNF,, LT, and their receptors are incompletely defined, ideal comparisons of the effects of LPS with these cytokines in sheep would include studies that use sheep TNF a and LT, which are presently unavailable, rather than human recombinant TNF a and LT. In addition, measurements of plasma levels of cytokines produced by sheep, rather than rabbits, after LPS challenge should guide dose determinations of future ovine studies with TNF O and LT. Physiological responses caused by synergy between the recombinant cytokines and contaminating LPS in the cytokine preparations are likely to be minor, because LAL assay measured very low levels of LPS.
Comparison of simultaneous lung lymph and arterial plasma levels of 6-k-PGF la after infusion of either LPS or rhTNF,, reveals that lymph levels consistently exceeded plasma levels. These results suggest that the high lymph levels of prostacyclin do not increase solely by diffusion of plasma prostacyclin derived from extrapulmonary sources into lung interstitium; the lung produces large quantities of prostacyclin. A similar comparison of TXB2 levels suggests that LPS induces pulmonary production of thromboxane. Both pulmonary intravascular macrophages 31 and pulmonary vascular endothelium may contribute importantly to the release of thromboxane 32 and prostacyclin, respectively. Other investigators have also suggested that LPS induces pulmonary release of thromboxane and prostacyclin in sheep.
z7 -Differences between lymph and plasma 6-k-PGF, a levels in sheep given either LPS or rhTNF a may be due to multiple factors. The delay between LPS stimulation of macrophages and subsequent TNF a release probably contributes to the one hour delay before lymph 6-k-PGF lo levels increase significantly; however, this does not explain the decline of 6-k-PGF la levels in LPS-treated sheep to baseline values after 4 hours. Lung lymph 6-k-PGF, a levels were elevated throughout the study after rhTNF o infusion. The doses of rhTNF a we infused may produce higher plasma levels of TNF O than would be produced by infusion of 1 /xg/kg LPS. In addition, the functional half-lives of rhTNF a and LPS may differ. It is also possible that LPS injures endothelial cells, an important source of prostacyclin, to such an extent that prostacyclin synthesis decreases.
In summary, we discovered major differences between the ovine responses to infusion of 1 jxg/kg E. coU LPS, 25-150 /xg/kg rhTNF,,, and 25 jxg/kg rhLT. Whereas both LPS and 25-150 /ig/kg rhTNF a acutely caused severe leukopenia and, after 6 hours, comparably increased PAP and PVRI, rhTNF a caused more rapid and prolonged prostacyclin release into lung lymph and plasma, profound systemic vasodilation, and more rapid systemic hypotension than did LPS. LPS acutely caused greater thromboxane release into lung lymph and plasma, pulmonary vasoconstriction, and greater acute pulmonary hypertension. In addition, LPS caused a greater increase of pulmonary microvascular permeability after 6 hours than did rhTNF^ which may have induced only a minor permeability increase. rhLT infusion caused marked acute leukopenia and progressive systemic vasodilation but few of the other changes measured after challenge with either LPS or rhTNF Q . By studying doses of rhTNFr hLT, and LPS that caused some comparable physiological responses in the sheep, we identified several important differences of response.
